The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
PI3K/PTEN signaling in tumorigenesis and angiogenesis
Open accessAbstract
The phosphatidyl inositol 3-kinase (PI3K) can be activated by a variety of extracellular signals and involved in a number of cellular processes including cell proliferation, survival, protein synthesis, and tumor growth. Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is an antagonist of PI3K. The alterations of PI3K pathway such as activation of oncogenes, gene amplification, and inactivation of tumor suppressors, commonly occur in many human cancers. Angiogenesis is required for tumor growth and metastasis when the tumor reaches more than 1 mm in diameter. Recent studies have shown that PI3K and Akt play an important role in regulating tumor growth and angiogenesis through VEGF and HIF-1 expression. PI3K regulates the expression of these two proteins through HDM2 and p70S6K1 in human cancer cells. The frequent dysregulation of the PI3K/PTEN pathway in human cancer demonstrates that this pathway is an appropriate target for cancer therapeutics. In this review, we describe the recent advances in understanding the PI3K/PTEN pathway, the role and mechanism of PI3K in regulating tumor growth and angiogenesis, and the potential therapeutic opportunities for targeting this pathway for cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pedrero, J. M. G., Carracedo, D. G., Pinto, C. M., Zapatero, A. H., Rodrigo, J. P., Nieto, C. S., & Gonzalez, M. V. (2005) · International Journal of Cancer · doi:10.1002/ijc.20711 · Cited by 235
RetractedAngiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Self-citationThe phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Risau, W. (1997) · Nature · doi:10.1038/386671a0 · Cited by 5,727
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction
Burgering, B. M. T., & Coffer, P. J. (1995) · Nature · doi:10.1038/376599a0 · Cited by 2,089
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,006
Carmeliet, P., Lampugnani, M.-G., Moons, L., Breviario, F., Compernolle, V., Bono, F., Balconi, G., Spagnuolo, R., Oosthuyse, B., Dewerchin, M., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)81010-7 · Cited by 1,283
Folkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209
PIK3CA is implicated as an oncogene in ovarian cancer
Shayesteh, L., Lu, Y., Kuo, W.-L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., & Gray, J. W. (1999) · Nature Genetics · doi:10.1038/5042 · Cited by 1,155
Dimerization, DNA Binding, and Transactivation Properties of Hypoxia-inducible Factor 1
Jiang, B.-H., Rue, E., Wang, G. L., Roe, R., & Semenza, G. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.17771 · Cited by 1,106
Self-citationMutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 916
Brognard, J., Clark, A. S., Ni, Y., & Dennis, P. A. (2001) · PubMed · Cited by 905
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Suzuki, A., de la Pompa, J. L., Stambolic, V., Elia, A. J., Sasaki, T., Barrantes, I. D. B., Ho, A., Wakeham, A., ltie, A., Khoo, W., et al. (1998) · Current Biology · doi:10.1016/s0960-9822(07)00488-5 · Cited by 818
Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., & Testa, J. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3636 · Cited by 793
Staal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 767
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 694
Angiopoietin-1 Inhibits Endothelial Cell Apoptosis via the Akt/Survivin Pathway
Papapetropoulos, A., Fulton, D., Mahboubi, K., Kalb, R. G., O'Connor, D. S., Li, F., Altieri, D. C., & Sessa, W. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.13.9102 · Cited by 641
Oncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Velculescu, V. E. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1164 · Cited by 538
Jiang, B.-H., Zheng, J. Z., Aoki, M., & Vogt, P. K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040560897 · Cited by 528
Self-citationPIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas
Lee, J. W., Soung, Y. H., Kim, S. Y., Lee, H. W., Park, W. S., Nam, S. W., Kim, S. H., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2005) · Oncogene · doi:10.1038/sj.onc.1208304 · Cited by 506
Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors
Lindsley, C. W., Zhao, Z., Leister, W. H., Robinson, R. G., Barnett, S. F., Defeo-Jones, D., Jones, R. E., Hartman, G. D., Huff, J. R., Huber, H. E., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.11.011 · Cited by 503
Nakatani, K., Thompson, D. A., Barthel, A., Sakaue, H., Liu, W., Weigel, R. J., & Roth, R. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21528 · Cited by 475
Chan, S., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., Eiermann, W., Hess, D., Morant, R., Semiglazov, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.66.130 · Cited by 468
High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma
Oda, K., Stokoe, D., Taketani, Y., & McCormick, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2620 · Cited by 466
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.
Philp, A., Campbell, I., Leet, C. S. F., Vincan, E., Rockman, S., Whitehead, R. H., Thomas, R. J., & Phillips, W. A. (2001) · PubMed · Cited by 455
BARNETT, S. F., DEFEO-JONES, D., FU, S., HANCOCK, P. J., HASKELL, K. M., JONES, R. E., KAHANA, J. A., KRAL, A. M., LEANDER, K., LEE, L. L., et al. (2005) · Biochemical Journal · doi:10.1042/bj20041140 · Cited by 396
Cong, L.-N., Chen, H., Li, Y., Zhou, L., McGibbon, M. A., Taylor, S. I., & Quon, M. J. (1997) · Molecular Endocrinology · doi:10.1210/me.11.13.1881 · Cited by 384
Yang, L., Dan, H. C., Sun, M., Liu, Q., Sun, X.-M., Feldman, R. I., Hamilton, A. D., Polokoff, M., Nicosia, S. V., Herlyn, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0343 · Cited by 371
Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines
Hollestelle, A., Elstrodt, F., Nagel, J. H. A., Kallemeijn, W. W., & Schutte, M. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0263 · Cited by 320
Gao, N., Flynn, D. C., Zhang, Z., Zhong, X.-S., Walker, V., Liu, K. J., Shi, X., & Jiang, B.-H. (2004) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00422.2003 · Cited by 307
Self-citationRole of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer
Gao, N., Zhang, Z., Jiang, B.-H., & Shi, X. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.09.132 · Cited by 275
Self-citationConditional loss of PTEN leads to precocious development and neoplasia in the mammary gland
Li, G., Robinson, G. W., Lesche, R., Martinez-Diaz, H., Jiang, Z., Rozengurt, N., Wagner, K.-U., Wu, D.-C., Lane, T. F., Liu, X., et al. (2002) · Development · doi:10.1242/dev.129.17.4159 · Cited by 272
Prognostic Significance of Activated Akt Expression in Pancreatic Ductal Adenocarcinoma
Yamamoto, S., Tomita, Y., Hoshida, Y., Morooka, T., Nagano, H., Dono, K., Umeshita, K., Sakon, M., Ishikawa, O., Ohigashi, H., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-02-1441 · Cited by 241
Knobbe, C. B., & Reifenberger, G. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00481.x · Cited by 238
Lee, S., Choi, E.-J., Jin, C., & Kim, D.-H. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.11.051 · Cited by 230
Somatic mutation and gain of copy number of PIK3CA in human breast cancer
Wu, G., Xing, M., Mambo, E., Huang, X., Liu, J., Guo, Z., Chatterjee, A., Goldenberg, D., Gollin, S. M., Sukumar, S., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1262 · Cited by 228
Khwaja, A., Lehmann, K., Marte, B. M., & Downward, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.30.18793 · Cited by 213
The Role of Glycogen Synthase Kinase 3β in Insulin-stimulated Glucose Metabolism
Summers, S. A., Kao, A. W., Kohn, A. D., Backus, G. S., Roth, R. A., Pessin, J. E., & Birnbaum, M. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.25.17934 · Cited by 212
PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis
Fang, J., Ding, M., Yang, L., Liu, L.-Z., & Jiang, B.-H. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.07.025 · Cited by 205
Self-citationLiu, L.-Z., Hu, X.-W., Xia, C., He, J., Zhou, Q., Shi, X., Fang, J., & Jiang, B.-H. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.08.003 · Cited by 205
Self-citationTazzari, P. L., Cappellini, A., Ricci, F., Evangelisti, C., Papa, V, Grafone, T., Martinelli, G., Conte, R., Cocco, L., McCubrey, J. A., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404523 · Cited by 196
Downstream Signalling Events Regulated by Phosphatidylinositol 3-Kinase Activity
Duronio, V., Scheid, M. P., & Ettinger, S. (1998) · Cellular Signalling · doi:10.1016/s0898-6568(97)00129-0 · Cited by 192
Skinner, H. D., Zheng, J. Z., Fang, J., Agani, F., & Jiang, B.-H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404097200 · Cited by 192
Self-citationLiu, L.-Z., Zhou, X.-D., Qian, G., Shi, X., Fang, J., & Jiang, B.-H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4261 · Cited by 189
Self-citationSequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms
Nakayama, K., Nakayama, N., Kurman, R. J., Cope, L., Pohl, G., Samuels, Y., Velculescu, V. E., Wang, T.-L., & Shih, I.-M. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.7.2751 · Cited by 187
Byun, D., Cho, K., Ryu, B., Lee, M., Park, J., Chae, K., Kim, H., & Chi, S. (2003) · International Journal of Cancer · doi:10.1002/ijc.10962 · Cited by 184
Granville, C. A., Memmott, R. M., Gills, J. J., & Dennis, P. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1654 · Cited by 181
Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival.
Ermoian, R. P., Furniss, C. S., Lamborn, K. R., Basila, D., Berger, M. S., GOTTSCHALK, A. R., Nicholas, M. K., Stokoe, D., & Haas-Kogan, D. A. (2002) · PubMed · Cited by 180
DeFeo-Jones, D., Barnett, S. F., Fu, S., Hancock, P. J., Haskell, K. M., Leander, K. R., McAvoy, E., Robinson, R. G., Duggan, M. E., Lindsley, C. W., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.271.4.2 · Cited by 173
Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition
Han, E. K.-H., Leverson, J. D., McGonigal, T., Shah, O. J., Woods, K. W., Hunter, T., Giranda, V. L., & Luo, Y. (2007) · Oncogene · doi:10.1038/sj.onc.1210343 · Cited by 168
PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme
Gallia, G. L., Rand, V., Siu, I.-M., Eberhart, C. G., James, C. D., Marie, S. K. N., Oba-Shinjo, S. M., Carlotti, C. G., Caballero, O. L., Simpson, A. J. G., et al. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0172 · Cited by 161
Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten
Backman, S. A., Ghazarian, D., So, K., Sanchez, O., Wagner, K.-U., Hennighausen, L., Suzuki, A., Tsao, M.-S., Chapman, W. B., Stambolic, V., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308217100 · Cited by 159
Lee, J. T., Steelman, L. S., & McCubrey, J. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1612 · Cited by 156
Martelli, A. M., Tazzari, P. L., Tabellini, G., Bortul, R., Billi, A. M., Manzoli, L., Ruggeri, A., Conte, R., & Cocco, L. (2003) · Leukemia · doi:10.1038/sj.leu.2403044 · Cited by 155
Ihle, N. T., Paine-Murrieta, G. D., Berggren, M. I., Baker, A. F., Tate, W. R., Wipf, P., Abraham, R. T., Kirkpatrick, D. L., & Powis, G. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0149 · Cited by 154
Bertelsen, B. I., Steine, S. J., Sandvei, R., Molven, A., & Lærum, O. D. (2005) · International Journal of Cancer · doi:10.1002/ijc.21461 · Cited by 153
Inactivation of thePTEN/MMAC1/TEP1 gene in human lung cancers
Kohno, T., Takahashi, M., Manda, R., & Yokota, J. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199806)22:2<152::aid-gcc10>3.0.co;2-s · Cited by 147
Mutation and Allelic Loss of the PTEN/MMAC1 gene in Primary and Metastatic Melanoma Biopsies
Birck, A., Ahrenkiel, V., Zeuthen, J., HOU-JENSEN, K., & Guldberg, P. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00877.x · Cited by 141
Genetic Alterations of Phosphoinositide 3‐kinase Subunit Genes in Human Glioblastomas
Mizoguchi, M., Nutt, C. L., Mohapatra, G., & Louis, D. N. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00080.x · Cited by 136
Alternate molecular genetic pathways in ovarian carcinomas of common histological types
Willner, J. B., Wurz, K., Allison, K. H., Galic, V., Garcia, R. L., Goff, B. A., & Swisher, E. M. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.10.007 · Cited by 124
Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components
Actor, B., Cobbers, J. M. J. L., Büschges, R., Wolter, M., Knobbe-Thomsen, C. B., Reifenberger, G., & Weber, R. G. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10087 · Cited by 124
Castillo, S. S., Brognard, J., Petukhov, P. A., Zhang, C., Tsurutani, J., Granville, C. A., Li, M., Jung, M., West, K. A., Gills, J. G., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1530 · Cited by 124
Arbiser, J. L., Kau, T. R., Konar, M., Narra, K. K., Ramchandran, R., Summers, S. A., Vlahos, C. J., Ye, K., Perry, B. N., Matter, W. F., et al. (2006) · Blood · doi:10.1182/blood-2006-06-029934 · Cited by 111
Phosphoinositide 3-kinases as drug targets in cancer
Stephens, L., WILLIAMS, R., & Hawkins, P. T. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.03.002 · Cited by 106
EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma
Livasy, C., Reading, F. C., Moore, D., Boggess, J. F., & Lininger, R. A. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.07.124 · Cited by 104
Święch-Zubilewicz, A., Hecquet, C., Jeanny, J., Soubrane, G., Courtois, Y., & Mascarelli, F. (2001) · Oncogene · doi:10.1038/sj.onc.1204231 · Cited by 89
Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells
Jin, X., Gossett, D. R., Wang, S., Yang, D., Cao, Y., Chen, J. C., Guo, R., Reynolds, R. K., & Lin, J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602214 · Cited by 74
van Dam, P. A., Vergote, I. B., Lowe, D. G., Watson, J. V., Damme, P. V., van der Auwera, J.-C., & Shepherd, J. H. (1994) · Journal of Clinical Pathology · doi:10.1136/jcp.47.10.914 · Cited by 73
Regulation of angiogenesis and tumor growth by p110 Alpha and AKT1 via VEGF expression
Xia, C., Meng, Q., Cao, Z., Shi, X., & Jiang, B. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20707 · Cited by 71
Self-citationHarima, Y., Sawada, S., Nagata, K., Sougawa, M., Ostapenko, V., & Ohnishi, T. (2001) · International Journal of Oncology · doi:10.3892/ijo.18.3.493 · Cited by 64
Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma
Ollikainen, M., Gylling, A., Puputti, M., Nupponen, N. N., Abdel‐Rahman, W. M., Bützow, R. C., & Peltomäki, P. (2007) · International Journal of Cancer · doi:10.1002/ijc.22768 · Cited by 62
Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines
Whyte, D. B., & Holbeck, S. L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.025 · Cited by 60
Feun, L. G., Blessing, J. A., Barrett, R. J., & Hanjani, P. (1993) · American Journal of Clinical Oncology · doi:10.1097/00000421-199312000-00010 · Cited by 59
Oh, J. S., Kucab, J. E., Bushel, P. R., et al. (2002) · Neoplasia · doi:10.1038/sj.neo.7900229 · Cited by 57
In Vivo Molecular Pharmacology and Antitumor Activity of the Targeted Akt Inhibitor PX-316
Meuillet, E. J., Ihle, N. T., Baker, A. F., Gard, J. M. C., Stamper, C., Williams, R. R., Coon, A., Mahadevan, D., George, B. L., Kirkpatrick, L., et al. (2004) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/0965040042380487 · Cited by 53
Insulin-induced vascular endothelial growth factor expression is mediated by the NADPH oxidase NOX3
Carnésecchi, S., Carpentier, J., Foti, M., & Szántó, I. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.07.003 · Cited by 53
Novel Mutations of Epidermal Growth Factor Receptor in Localized Prostate Cancer
Diah, A. D. (2006) · Frontiers in bioscience · doi:10.2741/1986 · Cited by 35
Ursø, B., Brown, R. A., O’Rahilly, S., Shepherd, P. R., & Siddle, K. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01388-5 · Cited by 25
Research works printed but not linked: 5
- Ward, 2003, Isoform-specific phosphoinositide, 3, 426
- Hennessy, 2005, Exploiting the PI3K/AKT pathway for cancer drug discovery, Nat. Rev., Drug Discov., 4, 988, 10.1038/nrd1902 · DOI · Paper page
- Shayesteh, 1999, PIK3CA is implicated as an oncogene in ovarian cancer, Nat. Genet., 21, 99, 10.1038/5042 · DOI · Paper page
- Actor, 2002, Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components, Genes Chromosomes, Cancer, 34, 416
- Tang, 2006, A small molecule compound inhibits AKT pathway in ovarian cancer cell lines, Gynecol. Oncol., 100, 308, 10.1016/j.ygyno.2005.08.044 · doi:10.1016/j.ygyno.2005.08.044
Cited by
Nanomaterials for Theranostics: Recent Advances and Future Challenges
Lim, E.-K., Kim, T., Paik, S., Haam, S., Huh, Y.-M., & Lee, K. (2015) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,233
Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B.-S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1012 · Cited by 860
Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies
Adams, D. M., Trenor, C. C., Hammill, A. M., Vinks, A. A., Patel, M. N., Chaudry, G., Wentzel, M. S., Mobberley-Schuman, P. S., Campbell, L. M., Brookbank, C., et al. (2016) · Pediatrics · doi:10.1542/peds.2015-3257 · Cited by 844
Chromone: A Valid Scaffold in Medicinal Chemistry
Gaspar, A., Matos, M. J., Garrido, J., Uriarte, E., & Borges, F. (2014) · Chemical Reviews · doi:10.1021/cr400265z · Cited by 760
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
(2009) · Advances in Cancer Research · doi:10.1016/s0065-230x(09)02002-8 · Cited by 620
Metadata
- Authors
- Jiang, B.-H., & Liu, L.-Z.
- Venue
- Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
- Publisher
- Elsevier BV
- Published
- 2008-01
- Volume
- 1784
- Issue
- 1
- Pages
- 150-158
- ISSN
- 1570-9639 (ISSN-L)
- OpenAlex
- W2081467680
- Cited by
- 345
- References
- 88
- FWCI
- 11.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.